Jasper Therapeutics 10-Q Flags Going Concern Risk Despite $132M Kira Merger Financing
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.1× avg).
Summary
Jasper Therapeutics' first post-merger 10-Q reiterates going concern doubts, discloses a $30M CVR tied to briquilimab's FDA voucher, and reveals a Nasdaq delisting risk with a November 30 deadline.
Key Events · Earnings and Guidance · JSPR
-
Going Concern Warning Reiterated
Substantial doubt about the company's ability to continue as a going concern is stated in the 10-Q, driven by a potential obligation to repurchase Non-Voting Convertible Preferred Stock if stockholder approval for conversion is not obtained within 12 months.
-
Cash Position and PIPE Proceeds
Cash and cash equivalents were $7.3 million as of June 30, 2026. The $132.0 million PIPE financing closed on July 20, 2026, providing near-term runway but not eliminating the going concern risk.
-
Nasdaq Delisting Risk
A Nasdaq deficiency notice was received on June 3, 2026 for failing to maintain a $1.00 minimum bid price. The company has until November 30, 2026 to regain compliance, with a reverse stock split as a possible remedy.
-
Contingent Value Rights (CVR)
Each pre-merger Jasper shareholder received one CVR entitling them to a pro rata share of $30.0 million if the FDA issues a Priority Review Voucher for briquilimab by December 31, 2028.
Analysis · JSPR · Life Sciences
The first quarterly report following the Kira Pharmaceuticals merger and $132 million PIPE financing has been filed by Jasper Therapeutics. A going concern warning is reiterated in the 10-Q, citing the potential obligation to repurchase the Non-Voting Convertible Preferred Stock if stockholders do not approve conversion within 12 months. Only $7.3 million in cash was on hand as of June 30, 2026, before the PIPE proceeds arrived on July 20. The filing also discloses a $30 million contingent value right tied to an FDA priority review voucher for briquilimab, a new Mirador license agreement with up to $458.5 million in potential milestone payments, and a Nasdaq minimum bid price deficiency with a November 30, 2026 compliance deadline. These details materially expand on the merger announcement and highlight significant liquidity and listing risks.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.5M. The 52-week trading range was $0.32 to $3.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.